Purpose: The role of levetiracetam in different epileptic, nonepileptic, neurologic, and psychiatric disorders is discussed. Summary: Levetiracetam, an antiepileptic drug (AED), was first approved ...

Return on investment - most recent fiscal year 16.16 ...

Shorvon et al. [20] conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and tolerability of levetiracetam as add-on therapy in patients with ...

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Competition page helps you compare Cipla Ltd. with its sector peers on key parameters.

Cipla Fined Rs 1 Crore by GST Authority for Credit Claim Pharma company Cipla has been fined over Rs 1 crore by the GST authority for allegedly claiming inadmissible credit. The company plans to ...

Cipla is currently priced at Rs 1477.50, showing a modest increase of 0.38% today. The 5-day exponential moving average stands at Rs 1490.97, suggesting a stable trend in its recent performance. Cipla ...

Cipla Ltd. promoters Samina Hamied and Rumana Hamied will exit the pharmaceutical company and offload stakes worth Rs 2,004 crore through a block deal on Monday. The equity shares will be sold at Rs 1 ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Cipla shares rose 2.4 per cent in trade and recorded an intraday high at Rs 1,483.4 per share on BSE. On NSE, 1.022 million shares changed hands, while on BSE 0.019 million shares were traded. Around ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

Cipla Ltd.'s share price rose to become the top gainer on the NSE Nifty 50 index on Tuesday after Kotak Securities upgraded the stock rating to 'buy' from 'add'. The brokerage expects recovery in the ...